Pharmacological tightrope: risperidone's balancing act in cri du chat syndrome

This case report describes an infrequent instance of risperidone-induced hyperprolactinemia in a 23-year-old nonverbal male with cri du chat syndrome.

Risperidone, initially prescribed to manage aggressive behaviors, resulted in bilateral gynecomastia and hyperprolactinemia. Tapering of risperidone led to resolution of these symptoms but exposed a resurgence of excessive masturbation, a behavior previously suppressed by the medication. Reintroduction of risperidone controlled this behavior, suggesting its potential role in managing compulsive behaviors in this population.

This case underscores the complex interaction between pharmacological treatment and behavioral symptoms in neurodevelopmental disorders. It highlights the necessity for meticulous monitoring and individualized treatment approaches in managing such cases.

Initially prescribed for managing aggressive behaviors, Risperidone led to bilateral gynecomastia and hyperprolactinemia in the patient. Gradual tapering of Risperidone alleviated these symptoms but unveiled a resurgence of excessive masturbation, a behavior previously suppressed by the medication. Reintroduction of Risperidone mitigated this behavior, suggesting its potential efficacy in managing compulsive tendencies in this demographic.

This case highlights the intricate interplay between pharmacological interventions and the complex behavioral manifestations of neurodevelopmental disorders. It underscores the importance of vigilant monitoring and personalized treatment strategies in such cases.